The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting
predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G)
complement plays a primary role in disease pathogenesis. Herein we report the outcome of …

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Thrombotic microangiopathy can manifest in a diverse range of diseases and is
characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury …

Although the complement system is primarily perceived as a host defence system, a more
versatile, yet potentially more harmful side of this innate immune pathway as an …

The increasing number of clinical conditions that involve a pathological contribution from the
complement system—many of which affect the kidneys—has spurred a regained interest in …

Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …